VivoSim Labs, INC. (NASDAQ: VIVS)

Organovo Holdings, Inc. (ONVO) is a clinical-stage biotechnology company operating in the healthcare industry. The company's primary business activities revolve around its FXR program, which includes two clinically tested compounds, over 2,000 discovery or preclinical compounds, and FXR314, a drug that has demonstrated safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials. Organovo Holdings has FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis and plans to start a Phase 2a clinical trial in the same disease area in 2024.

Organovo Holdings' 3D human tissue platform is a versatile technology that the company applies agnostically to various tissues, intending to use the best 3D technology for a given disease. The company's proprietary NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Organovo Holdings has a broad portfolio of intellectual property rights covering the principles, enabling instrumentation, applications, tissue constructs, and methods of cell-based printing.

The company's revenue is primarily generated through its research and development activities, with a focus on the development of FXR314. Organovo Holdings has research collaborations with academic institutions, including Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia.

Organovo Holdings' employees are not represented by labor unions or covered under any collective bargaining agreements. The company considers its relationship with its employees to be good and has human capital resources objectives that include identifying, recruiting, retaining, incentivizing, and integrating its existing and additional employees.

The company's primary products are FXR314, a drug candidate for the treatment of inflammatory bowel disease, and its 3D human tissue platform. The company's primary customers are academic institutions, research organizations, and pharmaceutical companies.

Organovo Holdings faces intense competition in the biotechnology and pharmaceutical industry from major drug companies, specialized biotechnology firms, academic institutions, government agencies, and private and public research institutions. Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes. The company may require substantial additional funding, which could cause dilution to its existing stockholders and may restrict its operations or require it to relinquish rights to its technologies or to a product candidate.